61,346 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by Cerity Partners LLC

Cerity Partners LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 61,346 shares of the company’s stock, valued at approximately $656,000. Cerity Partners LLC owned approximately 0.14% of Immunome as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. TD Asset Management Inc acquired a new position in shares of Immunome in the 3rd quarter worth $1,063,000. Dorsey Wright & Associates acquired a new position in shares of Immunome in the 3rd quarter valued at $26,000. Finally, Acadian Asset Management LLC purchased a new position in Immunome in the 3rd quarter worth about $414,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Price Performance

IMNM opened at $14.66 on Wednesday. The company has a market capitalization of $875.06 million, a PE ratio of -2.72 and a beta of 1.66. The business has a 50-day moving average of $22.56 and a 200-day moving average of $15.07. Immunome, Inc. has a fifty-two week low of $4.44 and a fifty-two week high of $30.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.26). The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. On average, equities research analysts expect that Immunome, Inc. will post -1.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on IMNM shares. Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunome in a research note on Monday, January 29th. Guggenheim assumed coverage on Immunome in a research report on Monday, April 15th. They set a “buy” rating and a $35.00 price objective for the company. SVB Leerink started coverage on Immunome in a report on Monday, January 29th. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, Wedbush increased their target price on shares of Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a research report on Monday, April 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.67.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.